Wugen Inc., headquartered in St. Louis, Missouri, specializes in developing off-the-shelf allogeneic CAR-T cell therapies derived from healthy donor cells. The company focuses on addressing unmet needs in hematologic malignancies through its proprietary CAR-T platform, aiming to provide innovative solutions in the field of cancer treatment.